SENTI-202

Treatment Description

SENTI-202 is a kind of off-the-shelf immunotherapy that may work by modifiying natural killer cells using chimeric antigen receptors (CAR) to recognize and attack the CD33 and/or FLT3 antigen found on different kinds of cancer cells.

Participating Centers

There are 6 centers running trials with this treatment. Enter a location below to find the closest center.